(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Taiho Oncology, Inc.
Geron Corporation
Swedish Orphan Biovitrum
Bellicum Pharmaceuticals
Swedish Orphan Biovitrum
Kiadis Pharma
Merck Sharp & Dohme LLC
Novartis
Hoffmann-La Roche
Bristol-Myers Squibb
Amneal Pharmaceuticals, LLC